BR112023003310A2 - Vetores virais que codificam fusões de agonistas do receptor de glp-1 e usos dos mesmos no tratamento de doenças metabólicas - Google Patents

Vetores virais que codificam fusões de agonistas do receptor de glp-1 e usos dos mesmos no tratamento de doenças metabólicas

Info

Publication number
BR112023003310A2
BR112023003310A2 BR112023003310A BR112023003310A BR112023003310A2 BR 112023003310 A2 BR112023003310 A2 BR 112023003310A2 BR 112023003310 A BR112023003310 A BR 112023003310A BR 112023003310 A BR112023003310 A BR 112023003310A BR 112023003310 A2 BR112023003310 A2 BR 112023003310A2
Authority
BR
Brazil
Prior art keywords
receptor agonist
metabolic diseases
fusions
treatment
viral vectors
Prior art date
Application number
BR112023003310A
Other languages
English (en)
Portuguese (pt)
Inventor
M Wilson James
Hinderer Christian
Horiuchi Makoto
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of BR112023003310A2 publication Critical patent/BR112023003310A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112023003310A 2020-08-24 2021-08-24 Vetores virais que codificam fusões de agonistas do receptor de glp-1 e usos dos mesmos no tratamento de doenças metabólicas BR112023003310A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063069500P 2020-08-24 2020-08-24
PCT/US2021/047411 WO2022046815A1 (en) 2020-08-24 2021-08-24 Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases

Publications (1)

Publication Number Publication Date
BR112023003310A2 true BR112023003310A2 (pt) 2023-05-02

Family

ID=78032497

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003310A BR112023003310A2 (pt) 2020-08-24 2021-08-24 Vetores virais que codificam fusões de agonistas do receptor de glp-1 e usos dos mesmos no tratamento de doenças metabólicas

Country Status (9)

Country Link
US (1) US20230372539A1 (https=)
EP (1) EP4200429A1 (https=)
JP (1) JP7840319B2 (https=)
CN (1) CN116438312A (https=)
AU (1) AU2021332235A1 (https=)
BR (1) BR112023003310A2 (https=)
CA (1) CA3190399A1 (https=)
MX (1) MX2023002293A (https=)
WO (1) WO2022046815A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119173269A (zh) * 2022-03-03 2024-12-20 宾夕法尼亚州大学信托人 用于递送glp-1受体激动剂融合物的aav载体
GB202403805D0 (en) * 2024-03-15 2024-05-01 Ucl Business Ltd Compositions and methods of treatment
CN119351440B (zh) * 2024-12-25 2025-04-25 浙江大学衢州研究院 表达glp-1的重组载体、重组酵母及应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6548286B1 (en) 1997-04-14 2003-04-15 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant AAV product
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
US7201898B2 (en) 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
CN104327187B (zh) * 2014-10-11 2018-06-08 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
WO2017024198A1 (en) * 2015-08-06 2017-02-09 The Trustees Of The University Of Pennsylvania Glp-1 and use thereof in compositions for treating metabolic diseases
PT3589730T (pt) 2017-02-28 2024-02-28 Univ Pennsylvania Vetor de vírus adenoassociado (aav) de clado f e suas utilizações
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CA3112473A1 (en) * 2018-09-12 2020-03-19 Quiapeg Pharmaceuticals Ab Releasable glp-1 conjugates
CN110964116A (zh) * 2018-09-26 2020-04-07 北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc融合蛋白及其缀合物
WO2020184941A1 (en) * 2019-03-08 2020-09-17 Genexine, Inc. Glp-1 fusion proteins and uses thereof
SG11202111375RA (en) 2019-04-29 2021-11-29 Univ Pennsylvania Novel aav capsids and compositions containing same
WO2021081217A1 (en) * 2019-10-23 2021-04-29 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression

Also Published As

Publication number Publication date
US20230372539A1 (en) 2023-11-23
CA3190399A1 (en) 2022-03-03
MX2023002293A (es) 2023-05-19
WO2022046815A9 (en) 2022-05-19
JP2023543125A (ja) 2023-10-13
AU2021332235A1 (en) 2023-03-23
WO2022046815A1 (en) 2022-03-03
JP7840319B2 (ja) 2026-04-03
EP4200429A1 (en) 2023-06-28
CN116438312A (zh) 2023-07-14

Similar Documents

Publication Publication Date Title
BR112023003310A2 (pt) Vetores virais que codificam fusões de agonistas do receptor de glp-1 e usos dos mesmos no tratamento de doenças metabólicas
BR112021024786A2 (pt) Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
MX2022015079A (es) Variantes de hsd17b13 y usos de las mismas.
CO2018012096A2 (es) Proteínas de fusión gdf15 y usos de estas
JP2018528237A5 (https=)
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
BR112019011860A2 (pt) proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune
BR112017018728A2 (pt) sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada
BR112021026439A2 (pt) Vacina para febre suína africana
MX2020012350A (es) Anticuerpos anti-cd63, conjugados y usos de estos.
BR112018010639A2 (pt) método de transfecção transitória para produção retroviral.
MX2021000401A (es) Nuevas proteinas de fusion especificas para cd137 y pd-l1.
MX2021005555A (es) Vectores vegetales, composiciones y usos relacionados con los mismos.
MX2024010778A (es) Vectores de aav para administrar fusiones de agonistas de los receptores del glp-1
CO2021007916A2 (es) Ácido ribonucleico (arn) que codifica para una proteína
CL2023000419A1 (es) Terapia génica utilizando construcciones de ácidos nucleicos que comprenden secuencias promotoras de la proteína 2
AR095387A1 (es) Proteínas específicas para el baff y para la b7rp1 y sus usos
UY36616A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
MX2024010774A (es) Vectores virales que codifican fusiones de agonistas de los receptores del glp-2 y usos de estos para tratar el síndrome del intestino corto
Xu et al. Identification and functional analysis of two interferon regulatory factor 3 genes and their involvement in antiviral immune responses in the Chinese giant salamander Andrias davidianus
BR112019010933A2 (pt) construções de vetor viral para expressão de adjuvantes genéticos que ativam a via de sting
PE20190104A1 (es) Antigenos y anticuerpos de chagas y composiciones, metodos y usos de los mismos
AR123681A1 (es) FACTORES DE TRANSCRIPCIÓN DE PROTEÍNAS DE DEDOS DE ZINC NOVEDOSOS PARA LA REPRESIÓN DE LA EXPRESIÓN DE a-SINUCLEÍNA
BR112022018193A2 (pt) Vetor de expressão do fator 2 relacionado ao fator nuclear e2 humano e aplicação do vetor de expressão